Wayne Koberstein

  1. Companies To Watch: Synlogic
    5/31/2019

    Synlogic is an early-stage developer of “synthetic biotic” medicines — therapeutics consisting of beneficial microbes genetically engineered to treat rare metabolic diseases.

  2. Companies To Watch: Provention Bio
    5/1/2019

    This 15-person virtual biotech is trying to stop immune-mediated disease early, before it becomes a chronic condition.

  3. Medicines360 On A Mission For Women
    5/1/2019

    Medicines360 is using all its developed-world revenue to extend access to essential medicines to all women, regardless of the economic and healthcare circumstances in their part of the world.

  4. GlycoMimetics Aiming At Tough Targets
    5/1/2019

    An exclusive interview with Rachel King, a business person dedicated to a science-driven sector, who is CEO of GlycoMimetics, an oncology-focused biotechnology company.

  5. Garo Armen And Audacity At Agenus
    4/1/2019

    Garo Armen, CEO of Agenus and a long-time pharma industry veteran, has shown the instincts for simple money-making on one hand and the humanitarian side of biopharma on the other.

  6. Companies To Watch: Vyome Therapeutics
    4/1/2019

    Vyome Therapeutics has built platforms and is developing products that address antibiotic resistance in severe skin conditions.

  7. Companies-To-Watch 2018 Annual Roundup
    3/1/2019

    At the end of every year since we began the monthly column, Companies to Watch, I have gone back to the featured companies and asked each one to send me a short assessment of its progress since it appeared in Life Science Leader.

  8. Companies To Watch: Azitra
    3/1/2019

    Azitra is a small, young, early-stage company developing microbial biotherapeutics for conditions arising on the skin that can be addressed by using the microbiome.

  9. Industry Explorers Blaze On: Howard Fillit
    3/1/2019

    An in-depth look at  the career and accomplishments of Howard Fillit, M.D., who has long led the exploration of Alzheimer’s disease outside and inside of the biopharma industry.

  10. Three “Others” Of The New Oncology
    1/2/2019

    An in-depth look at three developers that exemplify the range of new approaches and alternatives in the IO combo space: Oncosec Medical, Heat Biologics, and Rexahn.